Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib
Authors:
- Benoit BeuselinckBBBenoit Beuselinck
- Diether LambrechtsDLDiether Lambrechts
- Thomas Van BrusselTBThomas Van Brussel
- Pascal WolterPWPascal Wolter
- Nina CardinaelsNCNina Cardinaels
- Steven JoniauSJSteven Joniau
- Evelyne LerutELEvelyne Lerut
- Alexandra KaradimouAKAlexandra Karadimou
- Gabrielle CouchyGCGabrielle Couchy
- Philippe SebePSPhilippe Sebe
- Alain RavaudARAlain Ravaud
- Marc ZerbibMZMarc Zerbib
- 30 May 2014
- journal article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 53 (10) , 1413-1422
Abstract
There is growing evidence that sunitinib plasma levels have an impact on treatment outcome in patients with metastatic renal cell carcinoma (mRCC). We studied the impact of single nucleotide polymorphisms (SNPs) in genes involved in sunitinib pharmacokinetics, and additionally, sunitinib pharmacodynamics on dose reductions of the tyrosine kinase inhibitor. We retrospectively analyzed germ-line DNA retrieved from mRCC patients receiving sunitinib as first-line therapy. We genotyped 11 key SNPs, respectively, in ABCB1, NR1/2, NR1/3 and CYP3A5, involved in sunitinib pharmacokinetics as well as VEGFR1 and VEGFR3, which have been suggested as regulators of sunitinib pharmacodynamics. Association between these SNPs and time-to-dose-reduction (TTDR) was studied by Cox regression. We identified 96 patients who were treated with sunitinib and from whom germ-line DNA and data on dose reductions were available. We observed an increased TTDR in patients carrying the TT-genotype in ABCB1 rs1125803 compared to patients with CC- or CT-genotypes (19 vs. 7 cycles; p = 0.031 on univariate analysis and p = 0.012 on multivariate analysis) and an increased TTDR in patients carrying the TT/TA-variant in ABCB1 rs2032582 compared to patients with the GG- or GT/GA-variant (19 vs. 7 cycles; p = 0.046 on univariate analysis and p = 0.024 on multivariate analysis). mRCC patients carrying the rs1128503 TT-variant or the TT/TA-variant in rs2032582 in ABCB1, which encodes for an efflux pump, do require less dose reductions due to adverse events compared to patients with the wild type or heterozygote variants in these genes.Keywords
This publication has 19 references indexed in Scilit:
- Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinibBritish Journal of Cancer, 2013
- VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysisActa Oncologica, 2013
- Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective studyThe Lancet Oncology, 2011
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With SunitinibJNCI: Journal of the National Cancer Institute, 2011
- Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with SunitinibClinical Cancer Research, 2011
- Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysisCancer Chemotherapy and Pharmacology, 2009
- Resistance to targeted therapy in renal-cell carcinomaThe Lancet Oncology, 2009
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology PatientsClinical Cancer Research, 2009
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007